The primary objective of this study is to determine the pharmacokinetic profile of a 50 mg/kg
loading dose of intravenous levetiracetam (LEV) in term and late preterm infants with
seizures. Secondary objectives are to evaluate the safety and efficacy of a 50 mg/kg loading
dose of levetiracetam in term and preterm infants with seizures, and to obtain data on steady
state drug levels of levetiracetam in neonates.